Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.87 |
| ▸ | CCR3 | P51677 | 20/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149277 | 1.00 | HRH1 (0.87) | HRH1CCR3KCNH2 | |
| SCHEMBL14110547 | 0.93 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180270 | 0.93 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180025 | 0.93 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL4157116 | 0.92 | HRH1 (0.74) | HRH1CCR3KCNH2 | |
| SCHEMBL180032 | 0.92 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180286 | 0.92 | HRH1 (0.98) | HRH1CCR3KCNH2 | |
| Hydrochloric Acid SCHEMBL14110672 | 0.92 | HRH1 (0.98) | HRH1CCR3KCNH2 | |
| SCHEMBL14110640 | 0.89 | HRH1 (0.77) | HRH1CCR3KCNH2 | |
| SCHEMBL180046 | 0.89 | HRH1 (0.92) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620400-B1 | piperidinylmethylpiperidine derivatives and their use as chemokine modulators | ASTRAZENECA AB (SE) | 2012-12-05 | — | — | EP | disclosed |
| US-20090118513-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-7495013-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-02-24 | — | — | US | disclosed |
| US-20070032523-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1620400-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004087659-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118513-A1 | Chemical Compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
| US-20070032523-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 35/4885CCR3 1/4885KCNH2 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.